NCT04353765

Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors

Non - Interventional, Retrospective Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 247 (actual)
• Sponsor: Ipsen · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To understand the epidemiology, treatment patterns and outcomes of patients with metastatic Renal Cell Carcinoma (mRCC). Data from mRCC patients who received cabozantinib versus non-cabozantinib Tyrosine Kinase Inhibitor (TKI) (a type of targeted cancer drug) immediately after Check Point Inhibitor (CPI) treatment (a type of immunotherapy that blocks proteins that stop the immune system from attacking the cancer cells) in US community oncology practices will be analyzed.

Conditions

• Locally Advanced or Metastatic Renal Cell Carcinoma

Interventions

Type	Name	Description
DRUG	Cabozantinib monotherapy	Intervention description (FDA Label): kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma (RCC).
DRUG	All authorized TKI monotherapies in advanced RCC per FDA label in advanced RCC	As per authorized FDA label in advanced RCC

Timeline

• Start date: 2020-01-30
• Primary completion: 2020-06-05
• Completion: 2020-06-05
• First posted: 2020-04-20
• Last updated: 2021-11-17

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study